Labeit, Bendix http://orcid.org/0000-0001-6094-3869
Berkovich, Elijahu
Claus, Inga
Roderigo, Malte
Schwake, Anna-Lena
Izgelov, Dvora
Mimrod, Dorit
Ahring, Sigrid
Oelenberg, Stephan
Muhle, Paul
Zentsch, Verena
Wenninger, Fiona
Suntrup-Krueger, Sonja
Dziewas, Rainer
Warnecke, Tobias
Funding for this research was provided by:
Clexio Bioscience Ltd.
Article History
Received: 1 May 2022
Accepted: 26 October 2022
First Online: 12 November 2022
Competing interests
: B.L.: has nothing to disclose. E.B.: was a Clexio Biosciences LTD employee at the time of study conduct but declares no competing non-financial interest. I.C.: has received honoraria from Abbvie but declares no competing non-financial interest. M.R.: has nothing to disclose. A.L.S.: has nothing to disclose. D.I.: was a Clexio Biosciences LTD employee at the time of study development and conduct but declares no competing non-financial interest. D.M.: was a Clexio Biosciences LTD employee at the time of study conduct but declares no competing non-financial interest. S.A.: has nothing to disclose. S.O.: has nothing to disclose. P.M.: has received honoraria from Abbvie, Fresenius Kabi, Nutricia, but declares no competing non-financial interest. V.Z.: has nothing to disclose. F.W.: has nothing to disclose. S.S.K.: has received research grants from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) and the Else Kröner-Fresenius-Stiftung but declares no competing non-financial interest. R.D.: has received honoraria from BMS, Daiichi Sankyo, Pfizer, Boehringer Ingelheim, Nutricia, Nestle, Olympus, but declares no competing non-financial interest. T.W.: has received honoraria from BIAL, Abbvie, Desitin, Pfitzer, and Licher, consultancies from Phagenesis, and funding from Abbvie, but declares no competing non-financial interest. Clexio Biosciences LTD is developing a system for oral drug delivery via a capsule with the size of the large capsule investigated in this study.